Minerva Neurosciences | NERV - Betriebsergebnis

Aktienkurs
6.52
Täglich Wechseln
-1.02 -13.53%
Monatlich
4.32%
Jährlich
252.43%
Q1 Prognose
7.31




Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Adma Biologics USD 62.75M 11.74M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Alterity Therapeutics Limited AUD -7.77M 2.99M 2023-06
AstraZeneca USD 2.97B 4.48B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Merck USD 6.24B 318M 2025-12
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 437M 2025-12
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Takeda JPY 168.82B 479.89B 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12